FERMENTALG |
Market Closed -
Other stock markets
|
Pre-market 02:26:49 am | |||
| 0.561 EUR | -2.60% |
|
0.56 | -0.18% |
| Apr. 12 | Fermentalg: transfer to Euronext Growth on April 16 | CF |
| Apr. 04 | Fermentalg SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +85.76% | 24.7M | - | ||
| +4.09% | 43.84B | B | ||
| +47.81% | 41.25B | A | ||
| +9.45% | 41.68B | B- | ||
| -10.92% | 27.04B | C | ||
| +9.32% | 25.53B | B- | ||
| -24.87% | 18.18B | B | ||
| +29.70% | 12.29B | C+ | ||
| +1.28% | 12.29B | C+ | ||
| +7.78% | 11.15B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALGAE Stock
- Ratings Fermentalg
